Cancer news and cancer widget
Sunday, October 19, 2008 ( change date )
Ardea Biosciences Initiates Phase 1/2 Study Of RDEA119, Its Lead MEK Inhibitor, In Combination With Nexavar® In Patients With Advanced Cancer
Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that it has initiated a Phase 1/2 study of RDEA119, its lead mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer, in combination with Nexavar, which is currently approved for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Medicalnewstoday.com Sunday, October 19, 2008ABRAXANE For Metastatic Breast Cancer Approved In Australia
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised Therapeutics Australia Pty Ltd, today announced that approval has been received from the Therapeutic Goods Administration (TGA) in Australia to market ABRAXANE® (nanoparticle albumin-bound paclitaxel) 100 mg powder for injection (suspension) for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.
Medicalnewstoday.com Sunday, October 19, 2008Start Of Phase 2 Study Of ACE-011 In Patients With Multiple Myeloma
Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 2 clinical study of its lead compound ACE-011 in patients with multiple myeloma. ACE-011 is being developed to treat bone loss associated with multiple myeloma and other cancers.
Medicalnewstoday.com Sunday, October 19, 2008Computer Model Reveals Cells' Inner Workings - MIT
After spending years developing a computational model to help illuminate cell signaling pathways, a team of MIT researchers decided to see what would happen if they "broke" the model. The results, reported in the Oct. 17 issue of the journal Cell, reveal new ways in which cells process chemical information and could indicate how to maximize the effectiveness of disease treatments such as chemotherapy.
Medicalnewstoday.com Sunday, October 19, 2008Researchers identify Achilles heel of common childhood tumor
(Harvard Medical School) Researchers have, for the first time, found a mechanism for the rapid growth of the benign blood vessel tumor known as infantile hemangiomas, the most common tumor found in children. The findings implicate gene mutations that facilitate the abnormal activity of a hormone called VEGF, and suggest that anti-VEGF therapies -- already approved for other conditions -- may be an effective treatment.
Eurekalert.org Sunday, October 19, 2008Self Exams for Women
Health care for women not only happens in the doctor's office, but also at home! There are a few self exams women can do at home to check for abnormalities...
About Sunday, October 19, 2008Skin Cancer Photo Gallery
Need to know what skin cancer loooks like? Check out these skin cancer pictures in our Skin Cancer Photo Gallery. You find examples of basal cell carcinoma, melanoma, and squamous...
About Sunday, October 19, 2008HPV: How Much Do You Know?
We have all heard about HPV from TV, the radio, and maybe even our doctors. That's largely due to the approval of the HPV vaccine, Gardasil. The commercials are informative,...
About Sunday, October 19, 2008
PREVIEW
OF YOUR NEWS WIDGET
INSTALL YOUR WIDGET